OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2. The company is ...
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
11h
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile ...
Earlier this month, Vanda Pharmaceuticals agreed to pay $10 million upfront for the license to Anaptys’ phase 3-stage pustular psoriasis drug imsidolimab.
Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...
Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback